⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DNTH News
Dianthus Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
DNTH
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
globenewswire.com
DNTH
Form 8-K
sec.gov
DNTH
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
globenewswire.com
DNTH
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
DNTH
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
DNTH
Form 8-K
sec.gov
DNTH
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
globenewswire.com
DNTH
Form 8-K
sec.gov
DNTH
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
globenewswire.com
DNTH